



**For Immediate Release
September 19, 2017**

SUNSHINE BIOPHARMA ANNOUNCES THE TERMS OF ITS BROKERED UP TO \$10 MILLION IN PRIVATE PLACEMENT FINANCING

Montreal, Quebec, Canada -- (ACCESSWIRE) -- Sunshine Biopharma Inc. (OTC Pink: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed negotiations of the terms of the previously announced private placement with its exclusive placement agent, Jitney Trade Inc. The offering will consist of up to 400,000,000 shares of the Company's Common Stock at a price of \$0.025 Canadian (approximately \$0.02 US) per share (the "Shares") for gross proceeds of up to \$10,000,000 Canadian (approximately \$8,000,000 US) (the "Offering"). If fully subscribed, the Shares will represent approximately 30.3% of the Company on a post Offering basis.

Management is very pleased with the outcome of the negotiations as it believes that the current trading price of the Common Stock does not reflect the real value of the Company, particularly in view of the recently obtained independent valuation report (the "Report"), which was announced on June 26, 2017, valuing the *en bloc* Fair Market Value of the Company's issued and outstanding shares at March 31, 2017, at between \$977 million and \$1,133 million. The Company had commissioned the Report as part of an obligation it had previously made to investors.

Upon closing of the Offering the Company intends to List its Common Stock on the TSX Venture Exchange in Toronto (Canada). The net proceeds derived from the Offering will be used for implementation of the Company's business plan including its Generic Pharmaceuticals Operations and Clinical Development of Adva-27a, the Company's flagship anticancer compound. Tests conducted on the Company's Adva-27a have demonstrated the drug's effectiveness at destroying multidrug resistant cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Uterine Sarcoma cells and Small-Cell Lung Cancer cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com